Navigation Links
Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
Date:8/15/2013

and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove sa
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
4. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
5. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
6. Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
7. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
8. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported ... The Company reported second quarter net sales of $1.18 ... currency over the second quarter of 2013.  Diluted earnings ... $1.49 adjusted, an increase of 4.2% adjusted over the ... was marked by solid sales growth in a number ...
(Date:7/24/2014)... July 24, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro ... measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 ... study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken. ... in the U.S. and affects millions of people worldwide.  ...
(Date:7/23/2014)... 2014 Announced at the 20 th ... agreement seeks to increase access to a promising new HIV ... 2014 conference in Melbourne today, the ... Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine ... in India and China ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2011, on Monday, November 7, 2011, ... November 7, at 5:00 p.m. Eastern Time / 2:00 p.m. ... and live webcast to provide a company update, as well ...
... Techne Corporation (NASDAQ: TECH ) announced that its ... $0.28 per share for the quarter ended September 30, 2011. ... all common shareholders of record on November 7, 2011.  Future ... on a quarterly basis. Techne Corporation has two ...
Cached Medicine Technology:Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 2Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 3Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011 4
(Date:7/24/2014)... University of Texas at Arlington professor who co-authored ... foundations engaged in community revitalization has been awarded ... 2014., Maria Martinez-Cosio, associate professor in the School ... award this week at the society,s national conference, ... lecturer and academic coordinator in the Urban Studies ...
(Date:7/24/2014)... of contents if you need to know precisely what substances ... to be a highly skilled chemist or to have genuine ... molecular structure of the various substances. Christian Grundahl Frankr, a ... has developed a method that allows him to use X-rays ... ,Fingerprints, of a Substance , The technique is called ,powder ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- A growing number of ... to boost their muscles and athletic ability, a new ... admit to using hGH jumped to 11 percent in ... in 2012, the new survey from the Partnership for ... a need for tighter regulation and oversight of performance-enhancing ...
(Date:7/24/2014)... a professional supplier of wedding dresses and special occasion gowns, ... of cheap wedding dresses to its online catalog. ... discounts. According to the CEO of the company, Stwd.co.uk is ... They are available at low rates, up to 55% off. ... previously priced at $150, and it is offered at a ...
(Date:7/24/2014)... 2014 Hayes, Inc. ( http://www.hayesinc.com ), ... use of evidence, is pleased to announce that Dee ... guest speaker at the AHRMM14 Conference in ... expert in value analysis who also serves as the ... Professionals (AHVAP), will facilitate and participate in two preconference ...
Breaking Medicine News(10 mins):Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 2Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 4Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 5Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3
... doctors' fail in recognizing cow's milk allergy in babies, which ... able to correctly diagnose the disease, wrongly recommending soy-based milk ... ,The survey of 500 doctors is being published ... by SHS International. The survey found out that most of ...
... practitioners need better resources and support to care for ... researchers. // ,In an editorial for ... general practice and family health specialists have outlined new ... in which partner violence is occurring. ...
... to treat bleeding disorders, like hemophilia, is being used to ... ,The drug Recombinant Activated Factor VIII has been proven ... can cause heart attacks, and strokes due to clot formation. ... to prescribe it to control life threatening blood loss. ...
... women boxers gathered here for the ongoing World Championships seem ... they stand a chance //of rupturing their womb muscles that ... simply after medals, for others, mostly foreign boxers, marriage is ... Indian pugilists - M.C. Mary Kom, 24, who is seeking ...
... eating reduces intake of food' – The general belief of ... of Rhode Island study confirms // that the concept of ... was bandied about for decades due to the lack of ... relation between slow eating and less calories intake. The study ...
... scientists at Dartmouth Medical School and Dartmouth College, have ... changing muscle metabolism and performance. // The researchers are ... of muscle diseases. , ,The researchers ... (or AMPK) is responsible for realizing the best muscle ...
Cached Medicine News:Health News:Majority Of Doctors Tend To Ignore Milk Allergy Cases In Babies 2Health News:Tackling Violence in Families 2Health News:As these women box on, do they risk becoming mothers? 2Health News:As these women box on, do they risk becoming mothers? 3Health News:Dartmouth researchers zero-in on a gene that heightens muscle performance 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: